• HOME
  •  > 
  • 薬学
  •  > 
  • 雑誌
  •  >  医学と薬学　79/11　2022年11月号

医学と薬学　79/11　2022年11月号

出版社： 自然科学社
発行日： 2022-10-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 潰瘍性大腸炎内科診療の新時代
電子書籍版： 2022-10-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　潰瘍性大腸炎内科診療の新時代

    序文
    潰瘍性大腸炎の病態
    　―クローン病との相違点は？
    潰瘍性大腸炎の診断と疾患活動性の評価
    日常診療に有用な潰瘍性大腸炎のバイオマーカー
    基本治療薬と投与上の注意点
    チオプリン製剤投与の最適化
    抗体製剤の特徴とその使い分け
    免疫抑制薬とJAK阻害薬

    研究
    　若年者で新型コロナワクチン3回目接種後に起きる副反応の特徴
    　　―2回目接種後との比較―

    Diagnosis
    　全自動化学発光酵素免疫測定装置ルミパルスL2400を用いた
    　　ルミパルスプレスト®LH，ルミパルスプレスト®FSH-Nの基礎的性能評価および
    　　ルミパルス®AMHの多嚢胞性卵巣症候群における測定値分布評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 潰瘍性大腸炎内科診療の新時代】

P.1449 掲載の参考文献
1) Goyette P, Boucher G, Mallon D, et al : High-density mapping of the MHC identifies a shared role for HLA-DRB1*01 : 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 47 : 172-179, 2015.
PubMed
2) Miceli-Richard C, Lesage S, Rybojad M, et al : CARD15 mutations in Blau syndrome. Nat Genet 29 : 19-20, 2001.
 
3) Mizoguchi A, Mizoguchi E, Takedatsu H, et al : Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16 : 219-230 2002.
PubMed
4) Goetz M, Atreya R, Ghalibafian M, et al : Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 13 : 1365-1368, 2007.
PubMed
5) Mallepally N, Abu-Sbeih H, Ahmed O, et al : Clinical Features of Rituximab-associated Gastrointestinal Toxicities. Am J Clin Oncol 42 : 539-545 2019.
PubMed
6) Mizoguchi A, Mizoguchi E, Chiba C, et al : Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 184 : 707-715, 1996.
PubMed
7) Piovani D, Danese S, Peyrin-Biroulet L, et al : Environmental Risk Factors for Inflammatory Bowel Diseases : An Umbrella Review of Meta-analyses. Gastroenterology 157 : 647-659.e4, 2019
 
8) Rubin DT, Rothe JA : The peri-appendiceal red patch in ulcerative colitis : review of the University of Chicago experience. Dig Dis Sci 55 : 3495-3501, 2010.
PubMed
9) Okazaki K, Onodera H, Watanabe N, et al : A patient with improvement of ulcerative colitis after appendectomy. Gastroenterol 119 : 502-506 2000.
 
10) Sahami S, Wildenberg ME, Koens L, et al : Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation : Short-Term Results of the PASSION Study. J Crohns Colitis 13 : 165-171, 2019.
PubMed
11) Stellingwerf ME, Sahami S, Winter DC, et al : Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis. Bri J Surgery 106 : 1697-1704, 2019.
 
12) Kaplan GG, Ng SC : Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology 152 : 313-321.e2, 2017.
 
13) Sugimoto K, Ogawa A, Mizoguchi E, et al : IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118 : 534-544, 2008.
 
14) Takeda K, Clausen BE, Kaisho T, et al : Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10 : 39-49, 1999.
PubMed
15) Durant L, Watford WT, Ramos HL, et al : Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32 : 605-615, 2010.
 
16) Mizoguchi A, Yano A, Himuro H, et al : Clinical importance of IL-22 cascade in IBD. J Gastroenterol 53 : 465-474, 2019.
 
17) Yoshimatsu Y, Sujino T, Miyamoto K, et al : Aryl hydrocarbon receptor signals in epithelial cells govern the recruitment and location of Helios+Tregs in the gut. Cell Rep 39 : 110773, 2022.
PubMed
18) Naganuma M, Sugimoto S, Mitsuyama K, et al : Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. Gastroenterology 154 : 935-947, 2018.
 
19) Matsuno Y, Hirano A, Torisu T, et al : Short-term and long-term outcomes of indigo naturalis treatment for inflammatory bowel disease. J Gastroenterol Hepatol 35 : 412-417, 2020.
PubMed
20) Sandborn WJ, Ghosh S, Panes J, et al : Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367 : 616-624, 2012.
PubMed
21) Panes J, Sandborn WJ, Schreiber S, et al : Tofacitinib for induction and maintenance therapy of Crohn's disease : results of two phase IIb randomised placebo-controlled trials. Gut 66 : 1049-1059, 2017.
PubMed
22) Vermeire S, Schreiber S, Petryka R, et al : Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study) : results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389 : 266-275, 2017.
PubMed
23) Macchi P, Villa A, Giliani S, et al : Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 : 65-68, 1995.
PubMed
24) Iijima H, Takahashi I, Kishi D, et al : Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med 190 : 607-615, 1999.
 
25) Mizoguchi A, Mizoguchi E, Bhan AK : The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice. Gastroenterology 116 : 320-326 1999.
 
P.1458 掲載の参考文献
1) Murakami Y, Nishiwaki Y, Oba M, et al : Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014 : an analysis of a nationwide survey. J Gastroenterol 54 : 1070-1077, 2019.
PubMed
2) 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」 (久松班) 令和2年度分担研究報告書 : 潰瘍性大腸炎・クローン病診断基準・治療指針 令和2年度改訂版, 2021.
 
3) Kishi M, Hirai F, Takatsu N, et al : A review on the current status and definitions of activity indices in inflammatory bowel disease : how to use indices for precise evaluation. J Gastroenterol 57 : 246-266, 2022.
PubMed
4) Truelove SC, Witts LJ : Cortisone in ulcerative colitis ; final report on a therapeutic trial. Br Med J 29 : 1041-1048, 1955.
 
5) Schroeder KW, Tremaine WJ, Ilstrup DM : Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 : 1625-1629, 1987.
PubMed
6) Turner D, Ricciuto A, Lewis A, et al : STRIDE-II : An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD) : Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 160 : 1570-1583, 2021.
 
7) Barreiro-de Acosta M, Vallejo N, de la Iglesia D : Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1) : A Longitudinal Cohort Study. J Crohns Colitis 10 : 13-19, 2019.
 
8) Vuitton L, Peyrin-Biroulet L, Colombel JF, et al : Defining endoscopic response and remission in ulcerative colitis clinical trials : an international consensus. Aliment Pharmacol Ther 45 : 801-812, 2017.
PubMed
9) Yokoyama K, Kobayashi K, Mukae M, et al : Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Pract 2013 : 192794, 2013.
PubMed
10) Mazzuoli S, Guglielmi FW, Antonelli E, et al : Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis 45 : 969-977, 2013.
PubMed
11) Carvalho PB, de Castro DF, Rosa B, et al : Mucosal healing in ulcerative colitis : when zero is better. J Crohns Colitis 10 : 20-25, 2016.
 
12) Nakarai A, Kato J, Hiraoka S, et al : Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol 20 : 18367-18374, 2014.
PubMed
13) Travis SP, Schnell D, Krzeski P, et al : Developing an instrument to assess the endoscopic severity of ulcerative colitis : the ulcerative colitis endoscopic index of severity (UCEIS). Gut 61 : 535-542, 2012.
PubMed
14) Travis SP, Schnell D, Krzeski P, et al : Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145 : 987-995, 2013.
PubMed
15) de Jong DC, Lowenberg M, Koumoutsos I, et al : Validation and investigation of the operating characteristics of the ulcerative colitis endoscopic index of severity. Inflamm Bowel Dis 25 : 937-944, 2019.
PubMed
16) Belvis Jimenez M, Hergueta-Delgado P, Gomez Rodriguez B, et al : Comparison of the mayo endoscopy score and the ulcerative colitis endoscopy index of severity and the ulcerative colitis colonoscopy index of severity. Endosc Int Open 9 : E130-E136, 2021.
PubMed
17) Corte C, Fernandopulle N, Catuneanu AM, et al : Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 9 : 376-381, 2015.
PubMed
18) Ikeya K, Hanai H, Sugimoto K, et al : The Ulcerative Colitis Endoscopic Index of Severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score. J Crohns Colitis 10 : 286-295, 2016.
 
19) Arai M, Naganuma M, Sugimoto S, et al : The Ulcerative Colitis Endoscopic Index of Severity is useful to predict medium- to long-term prognosis in ulcerative colitis patients with clinical remission. J Crohns Colitis 10 : 1303-1309, 2016.
 
20) Xie T, Zhang T, Ding C, et al : Ulcerative colitis endoscopic index of severity (UCEIS) versus Mayo endoscopic score (MES) in guiding the need for colectomy in patients with acute severe colitis. Gastroenterol Rep (Oxf) 6 : 38-44, 2018.
PubMed
21) Duricova D, Burisch J, Jess T, et al : Age-related differences in presentation and course of inflammatory bowel disease : an update on the population-based literature. Journal of Crohn's and Colitis 8 : 1351-1361, 2014.
PubMed
22) Turner D, Otley AR, Mack D, et al : Development, validation, and evaluation of a pediatrtic Ulcerative colitis activity index. Gastroenterology 133 : 423-432, 2007.
 
23) Mosli MH, Parker CE, Nelson SA, et al : Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 5 : CD011256, 2017.
PubMed
24) Romkens TEH, Kranenburg P, Tilburg AV, et al : Assessment of histological remission in ulcerative colitis : discrepancies between daily practice and expert opinion. J Crohn's Colitis 12 : 425-431, 2018.
 
25) Vashist NM, Samaan M, Mosli MH, et al : Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Datab Syst Rev 1 : CD011450, 2018.
 
26) Geboes K, Riddle R, Ost A, et al : A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47 : 404-409, 2000.
 
27) Tursi A, Elisei W, Picchio M, et al : Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment : a first "life" experience in primary gastroenterology centers in Italy. Ann Gastroenterol 27 : 369-373, 2014.
PubMed
28) Sandborn WJ, Feagan BG, Marano C, et al : Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 : 85-95, 2014.
PubMed
29) Colombel JF, Narula N, Peyrin BL : Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 152 : 351-361, 2017.
 
30) Roseth AG, Fagerhol MK, Aadland E, et al : Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 27 : 793-798, 1992.
PubMed
31) Khaki KF, Qujeq D, Kashifard M, et al : Calprotectin in inflammatory bowel disease. Clin Chim Acta 510 : 556-565, 2020.
 
32) Moum B, Jahnsen J, Bernklev T : Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 16 : 1091-1092, 2010.
PubMed
33) Meling TR, Aabakken L, Roseth A, et al : Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 31 : 339-344, 1996.
PubMed
34) Poullis A, Foster R, Mendall MA, et al : Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol 15 : 573-574, 2003.
PubMed
35) Vermeire S, Van Assche G, Rutgeerts P : Laboratory markers in IBD : useful, magic, or unnecessary toys? Gut 55 : 426-431, 2006.
PubMed
36) Yoshimura T, Mitsuyama K, Sakemi R, et al : Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease. Mediators Inflamm 2021 : 8825374, 2021.
PubMed
37) Shinzaki S, Matsuoka K, Tanaka H, et al : Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab : PLANET study. J Gastroenterol 56 : 560-569, 2021.
PubMed
38) Serada S, Fujimoto M, Terada F, et al : Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 18 : 2169-2179, 2012.
 
P.1465 掲載の参考文献
1) Tsuda S, Kunisaki R, Kato J, et al : Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 16 : 579-587, 2018.
PubMed
2) Nakarai A, Kato J, Hiraoka S, et al : Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. World J Gastroenterol 7 : 5079-5087, 2016.
 
3) Pepys MB, Hirschfield GM : C-reactive protein : a critical update. J Clin Invest 111 : 1805-1812, 2003.
PubMed
4) Mosli MH, Zou G, Garg SK, et al : C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients : A Systematic Review and Meta-Analysis. Am J Gastroenterol 110 : 802-819, 2015.
PubMed
5) Langhorst J, Elsenbruch S, Koelzer J, et al : Non invasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases : performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103 : 162-169, 2008.
 
6) Schoepfer AM, Beglinger C, Straumann A, et al : Ulcerative colitis : correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 15 : 1851-1858, 2009.
PubMed
7) Lobaton T, Rodriguez-Moranta F, Lopez A, et al : A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 19 : 1034-1042, 2013.
 
8) Hosomi S, Yamagami H, Itani S, et al : Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel desease. J Crohns Colitis 12 : 87-95, 2018.
 
9) Ishida N, Higuchi T, Miyazu T, et al : C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci Rep 11 : 12431. 2021.
PubMed
10) Iwasa R, Yamada A, Sono K, et al : C-reactive protein level at 2 weeks following initiation of infliximab induction therapy colitis : a 3 year follow-up study. BMC gastroenterol 15 : 103, 2015.
PubMed
11) Thomas RD, Westengard JC, Hay KL, et al : Calibration and validation for erythrocyte sedimentation tests. Role of the International Committee on Standardization in Hematology reference procedure. Arch Pathol Lab Med 117 : 719-723, 1993.
 
12) Sayar S, Kurbuz K, Kahraman R, et al : A practical marker to determining acute severe ulcerative colitis : CRP/albumin ratio. North Clin Istanb 7 : 49-55, 2019.
PubMed
13) Mak LY, Tong TSM, Cheung KS, et al : Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol 11 : e00138, 2020.
PubMed
14) Danese S, Motte Cd Cde L, Fiocchi C : Platelets in inflammatory bowel disease : clinical, pathogenic, and therapeutic implications. Am J Gastrotenterol 99 : 938-945, 2004.
 
15) Uchihara M, Kato J, Tsuda S, et al : Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis. J Gastroenterol Hepatol Open 1 : 98-104, 2017.
 
16) Nakarai A, Kato J, Hiraoka S, et al : An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing. Gut Liver 12 : 420-425, 2018.
PubMed
17) Jauregui-Amezaga A, Lopez-Ceron M, Aceituno M, et al : Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis : a prospective study. Inflamm Bowel Dis 20 : 1187-1193, 2014.
PubMed
18) Makela SM, Forssten SD, Kailajarvi M, et al : Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a nonsteroidal anti-inflammatory drug : A randomized, placebo-controlled, double-blind clinical trial. Br J Clin Pharmacol 87 : 4625-4635, 2021.
PubMed
19) Mari A, Baker FA, Mahamid M,et al : Clinical utility of fecal calprotectin : potential applications beyond inflammatory bowel disease for the primary care physician. Ann Gastroenterol 32 : 425-430, 2019.
PubMed
20) Lee SH, Kim MJ, Chang K, et al : Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol 17 : 110, 2017.
PubMed
21) Hiraoka S, Inokuchi T, Nakarai A, et al : Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis. Gut Liver 12 : 142-148, 2018.
PubMed
22) Urushikubo J, Yanai S, Nakamura S, et al : Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol 24 : 4384-4392, 2018.
PubMed
23) Frin AC, Filippi J, Boschetti G, et al : Accuracies of fecal calprotectin, lactoferrin, m2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Dig Liver Dis 49 : 11-16, 2017.
PubMed
24) De Vos M, Louis EJ, Jahnsen J, et al : Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 19 : 2111-2117, 2013.
 
25) Lasson A, Stotzer PO, Ohman L, et al : The intraindividual variability of faecal calprotectin : a prospective study in patients with active ulcerative colitis. J Crohns Colitis 9 : 26-32, 2015.
PubMed
26) Bermejo F, Algaba A, Bonillo D, et al : Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps. Gastroenterol Hepatol 43 : 73-78, 2020.
PubMed
27) 堀田真希, 山西八郎 : 一般検査の実例と工夫 上部消化管出血の検出はどうするか. 臨床病理レビュー 140 : 174-178, 2007.
 
28) Nakarai A, Kato J, Hiraoka S, et al : Evaluation of mucosal healing of ulcerative colitis be a quantitative fecal immunochemical test. Am J Gastroenterol 108 : 83-89, 2013.
PubMed
29) Kato J, Hiraoka S, Nakarai A, et al : Noninvasive evaluation of mucosal healing in inflammatory bowel diseases. Clin J Gastroenterol 6 : 1-7, 2013.
PubMed
30) Kato J, Hiraoka S, Nakarai A, et al : Fecal immunochemical test as a biomarker for inflammatory bowel diseases : can it rival fecal calprotectin? Intest Res 14 : 5-14, 2016.
PubMed
31) Hiraoka S, Kato J, Nakarai A, et al : Consecutive Measurements by Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Detect Clinical Relapse. J Crohns Colitis 10 : 687-694, 2016.
PubMed
32) Dai C, Jiang M, Sun M, et al : Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients : A systematic review and meta-analysis. J Gastroenterol Hepatol 33 : 990-997, 2018.
PubMed
33) 岡田茂治 : 5. 便潜血検査のピットフォール. Medical Technology 45 : 485-490, 2017.
Medical*Online
34) Haupt H, Baudner S : Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-gly-coprotein from human serum (author's transl). Hoppe Seylers Z Physiol Chem 358 : 639-646, 1977.
 
35) Serada S, Fujimoto M, Ogata A, et al : iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis 69 : 770-774, 2010.
PubMed
36) Naka T, Fujimoto M : LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease. Immunol Med 41 : 62-67, 2018.
PubMed
37) Serada S, Fujimoto M, Terabe F, et al : Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 18 : 2169-2179, 2012.
PubMed
38) Shinzaki S, Matsuoka K, Iijima H, et al : Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 11 : 84-91, 2017.
PubMed
39) Yasutomi E, Inokuchi T, Hiraoka S, et al : Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep 11 : 11086, 2021.
PubMed
40) Yanai S, Shinzaki S, Matsuoka K, et al : Leu-cine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease : A Sub-Analysis of the PLANET Study. Digestion 102 : 929-937, 2021.
 
41) Ludemann J, Utecht B, Gross WL : Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen. J Immunol Methods 114 : 167-174, 1998.
 
42) Pagnoux C : Updates in ANCA-associated vasculitis. Eur J Rheumatol 3 : 122-133, 2016.
PubMed
43) Quinton JF, Sendid B, Reumaux D, et al : Anti-saccharomyces cerecisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease : prevalence and diagnostic role. Gut 42 : 788-791, 1998.
 
44) Rump JA, Scholmerich J, Gross V, et al : A new colitis but not in Crohn's disease. Immunobiology 181 : 406-413, 1990.
 
45) Prideaux L, De Cruz P, Ng SC, et al : Serological antibodies in inflammatory bowel disease : a systematic review. Inflamm Bowel Dis 18 : 1340-1355, 2012.
PubMed
46) Xu J, Yang CH, Chen XY, et al : A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody. World J Gastroenterol 14 : 7012-7015, 2008.
 
47) Takedatsu H, Mitsuyama K, Fukunaga S, et al : Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol 33 : 1603-1607, 2018.
 
48) Aoyama Y, Inaba T, Takahashi S, et al : Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol 21 : 325, 2021.
PubMed
49) Elzouki AN, Eriksson S, Lofberg R, et al : The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis 5 : 246-252, 1999.
PubMed
50) Garcia-Herola A, Nos P, et al : Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and Crohn's disease. Gastroenterol Hepatol 21 : 169-173, 1998.
PubMed
51) Arias-Loste MT, Bonilla G, Moraleja I, et al : Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 45 : 109-116, 2013.
PubMed
52) Stinton LM, Bentow C, Mahler M, et al : PR3-ANCA : a promising biomarker in primary sclerosing cholangitis (PSC). PLoS One 9 : e112877, 2014.
PubMed
53) Yoshida A, Matsuoka K, Ueno F, et al : Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflamm Intest Dis 6 : 117-122, 2021.
 
54) Mandl LA, Solomon DH, Smith EL, et al : Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis : Can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 162 : 1509-1514, 2002.
PubMed
55) Shirai T, Takahashi R, Tajima Y, et al : Peripheral T cell lymphoma with a high titer of proteinase-3-antineutrophil cytoplasmic antibodies that resembled Wegener's granulomatosis. Intern Med 48 : 2041-2045, 2009.
PubMed
P.1476 掲載の参考文献
1) 持田製薬ホームページ : リアルダの作用機序. https://med.mochida.co.jp/medicaldomain/gastroenterology/lialda/info/mechanism.html (2022. 10. 14 アクセス)
 
2) Naganuma M, Iwao Y, Ogata H, et al : Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis : comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 7 : 221-225, 2001.
PubMed
3) 西尾昭宏, 中村志郎 : 潰瘍性大腸炎に対する5-ASA製剤をどのように使いこなすか. Mebio 34 : 18-26, 2017.
Medical*Online
4) Yoshino T, Makoto S, Yazumi S : Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterol 3 : e000103, 2016.
 
5) 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」 (久松班) 令和3年度分担研究報告書 : 潰瘍性大腸炎・クローン病 診断基準・治療指針 令和3年度改訂版, 令和4年3月, 2022.
 
6) 日本消化器病学会 編 : 炎症性腸疾患 (IBD) 診療ガイドライン 2020 改定第2版, 南江堂, 東京, 2020.
 
7) Nguyen NH, Mathurin Fumery M, Dulai PS, et al : Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis : a sysytematic and review and network meta-analyses. Lancet Gastroenterol Hepatol 3 : 742-753, 2018.
 
8) Di Paolo MC, Paoluzi OA, Pica R, et al : Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis : report on tolerance and side-effects. Dig Liv Dis 33 : 563-569, 2001.
 
9) Sehgal P, Colombel JF, Aboubakr A, et al : Systematic review : safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther 47 : 1597-1609, 2018.
PubMed
10) Hiraoka S, Fujiwara A, Toyokawa T, et al : Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol 36 : 137-143, 2021.
PubMed
11) Mizuno S, Ono K, Mikami Y et al : 5-Aminosalicylicacidintoleranceis associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res 18 : 69-78, 2020.
PubMed
12) Hibiya S, Matsuyama Y, Fuji T, et al : 5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis. Aliment Pharma col Ther 53 : 103-113, 2021.
 
13) Shimizu H, Arai K, Tang J et al : 5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis. Pediatr Int 59 : 583-587, 2017.
PubMed
14) Suzuki K, Kakuta Y, Naito T, et al : Genetic background of mesalamine-induced fever and diarrhrea in Japanese patients with inflammatory bowel disease. Inflamm Bowel Dis 28 : 21-31, 2022.
 
15) Truelove SC, Witts LJ : Cortisone in ulcerative colitis ; final report on a therapeutic trial. Br Med J 2 : 1041-1048, 1955.
PubMed
16) 川合眞一 : 鎮痛薬・ステロイド. ドクターサロン 62 : 53-57, 2018.
 
17) 杉田昭, 木村英明, 荒井勝彦, 他 : 外科治療. 日本臨床 63 : 859-866, 2005.
 
18) Ardizzone S, Cassinotti A, Duca P, et al : Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 9 : 483-489.e3, 2011.
 
19) Khan N, Abbas A, Williamson A, et al : Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci 58 : 2963-2969, 2013.
 
20) Mastuoka K, Igarashi A, Sato N, et al : Trends in corticosteroid pescription for ulcerstive colitis and factors asscosiated with long-term corticosteroid use : Analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis 15 : 358-366, 2021.
 
P.1483 掲載の参考文献
1) Ardizzone S, Maconi G, Russo A, et al : Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 : 47-53, 2006.
PubMed
2) Panaccione R, Ghosh S, Middleton S, et al : Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146 : 392-400e3, 2014.
PubMed
3) Kakuta Y, Kinouchi Y, Shimosegawa T : Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia : prospects for clinical application of NUDT15 genotyping. J Gastroenterol 53 : 172-180, 2018.
PubMed
4) Kakuta Y, Kawai Y, Okamoto D, et al : NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol 53 : 1065-1078, 2018.
PubMed
5) Tomiyoshi K, Sato H, Tominaga K, et al : Rare Genotype of His/His in NUDT15 Codon 139 and Thiopurine-associated Adverse Events in a Case of Ulcerative Colitis. Intern Med 59 : 1611-1613, 2020.
 
6) Heap GA, Weedon MN, Bewshea CM, et al : HLADQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 46 : 1131-1134, 2014.
PubMed
7) Kobayashi T, Uda A, Udagawa E, et al : Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease : A Large-Scale Administrative Database Analysis. J Crohns Colitis 14 : 617-623, 2020.
PubMed
8) Miura M, Shimizu H, Saito D, et al : Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study). J Gastroenterol 56 : 1080-1091, 2021.
PubMed
9) Tatsumi G, Kawahara M, Imai T, et al : Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15 (R138C) knock-in mice. Leukemia 34 : 882-894, 2020.
PubMed
10) Ando K, Fujiya M, Watanabe K, et al : A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan. J Gastroenterol 56 : 1062-1079, 2021.
 
P.1490 掲載の参考文献
1) Levin AD, Wildenberg ME, van den Brink GR : Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis 10 : 989-997, 2016.
PubMed
2) Rutgeerts P, Sandborn WJ, Feagan BG, et al : Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 353 : 2462-2476, 2005.
PubMed
3) Stidham RW, Lee TC, Higgins PD, et al : Systematic review with network meta-analysis : the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Alimentary Aliment Pharmacol Ther 39 : 660-671, 2014.
 
4) 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」 (久松班) 令和3年度分担研究報告書 : 潰瘍性大腸炎・クローン病 診断基準・治療指針 令和3年度改訂版, 令和4年3月, 2022.
 
5) Brandse JF, van den Brink GR, Wildenberg ME, et al : Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 149 : 350-355.e2, 2015.
 
6) Sandborn WJ, van Assche G, Reinisch W, et al : Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 142 : 257-265.e1-3, 2012.
 
7) Reinisch W, Sandborn WJ, Hommes DW, et al : Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial. Gut 60 : 780-787, 2011.
PubMed
8) Sandborn WJ, Feagan BG, Marano C, et al : Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 : 85-95 ; quiz e14-15, 2014.
 
9) Sandborn WJ, Feagan BG, Marano C, et al : Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 : 96-109.e1, 2014.
 
10) Miyasaka M, Tanaka T : Lymphocyte trafficking across high endothelial venules : dogmas and enigmas. Nat Rev Immunol 4 : 360-370, 2004.
PubMed
11) Feagan BG, Rutgeerts P, Sands BE, et al : Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 369 : 699-710, 2013.
PubMed
12) Sugiura T, Kageyama S, Andou A, et al : Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis 7 : e533-542, 2013.
PubMed
13) Van Assche G, Van Ranst M, Sciot R, et al : Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. N Engl J Med 353 : 362-368, 2005.
PubMed
14) Trinchieri G : Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 : 133-146, 2003.
PubMed
15) Pirhonen J, Matikainen S, Julkunen I : Regulation of Virus-Induced IL-12 and IL-23 Expression in Human Macrophages. J Immunol 169 : 5673-5678, 2002.
PubMed
16) Wilson NJ, Boniface K, Chan JR, et al : Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8 : 950-957, 2007.
PubMed
17) Friedrich M, Pohin M, Powrie F : Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 50 : 992-1006, 2019.
PubMed
18) Sands BE, Sandborn WJ, Panaccione R, et al : Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 381 : 1201-1214, 2019.
PubMed
19) Sandborn WJ, Su C, Sands BE, et al : Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 376 : 1723-1736, 2017.
PubMed
20) Feagan BG, Danese S, Loftus EV Jr, et al : Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION) : a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 397 : 2372-2384, 2021.
PubMed
21) Matsuoka K, Watanabe M, Ohmori T, et al : AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis : a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol 7 : 648-657, 2022.
 
22) Lasa JS, Olivera PA, Danese S, et al : Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis : a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 7 : 161-170, 2022.
PubMed
23) D'Amico F, Magro F, Peyrin-Biroulet L, et al : Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Journal of Crohn's and Colitis 16 : 835-844, 2022.
 
P.1496 掲載の参考文献
1) Lichtiger S, Present DH, Kornbluth A et al : Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 : 1841-1845, 1994.
PubMed
2) Laharie D, Bourreille A, Branche J et al : Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids : a parallel, open-label randomised controlled trial. Lancet 380 : 1909-1915, 2012.
PubMed
3) Ogata H, Matsui T, Nakamura M et al : A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55 : 1255-1262, 2006.
 
4) Ogata H, Kato J, Hirai F et al : Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 18 : 803-808, 2012.
PubMed
5) Bamba S, Andoh A, Imaeda H et al : Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med 4 : 99-104, 2012.
PubMed
6) Tarabar D, El Jurdi K, Traboulsi C et al : A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis : izab328, 2022. [Online ahead of print]
 
7) Sandborn WJ, Su C, Sands BE et al : Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 376 : 1723-1736,2017.
PubMed
8) Sandborn WJ, Peyrin-Biroulet L, Sharara AI et al : Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol 20 : 591-601.e8, 2021.
 
9) Hanauer S, Panaccione R, Danese S et al : Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 17 : 139-147, 2019.
PubMed
10) Kotwani P, Terdiman J, Lewin S : Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis : A Real-world Experience. J Crohns Colitis 14 : 1026-1028, 2020.
PubMed
11) Matsuoka K, Hisamatsu T, Kim HJ et al : Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. J Gastroenterol Hepatol, 2022. [Online ahead of print]
 
12) Ytterberg SR, Bhatt DL, Mikuls TR et al : Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386 : 316-326, 2022
PubMed

【研究】

P.1508 掲載の参考文献
1) 西野拓人, 風間逸郎 : 宮城県で発生した新型コロナウイルス感染症患者の特徴 第1波88名の集計から見えた問題点と今後の課題. 宮城大学研究ジャーナル 1 : 183-201, 2021.
 
2) Kazama I : Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19 : Can it be a novel therapeutic strategy? Drug Discov Ther 14 : 143-144, 2020.
PubMed
3) 先崎桃乃, 風間逸郎 : 研究レポート 若年者で新型コロナワクチン接種後に起きる副反応の特徴と病態生理に基づく対処法の検討. 看護技術 68 (1) : 60-67, 2022.
 
4) Kazama I, Senzaki M : Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects? Drug Discov Ther 15 : 278-280, 2021.
PubMed
5) Menni C, Klaser K, May A, et al : Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK : a prospective observational study. Lancet Infect Dis 21 : 939-949, 2021.
 
6) Kuhlmann C, Mayer C K, Claassen M, et al : Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 399 : 625-626, 2022.
PubMed
7) Tartof S Y, Slezak J M, Fischer H, et al : Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA : a retrospective cohort study. Lancet 398 : 1407-1416, 2021.
 
8) Butt A A, Dargham S R, Coyle P, et al : COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status. JAMA Intern Med. doi : 10.1001/jamainternmed.2022.3351, 2022.
 
9) Collie S, Champion J, Moultrie H, et al : Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med 386 : 494-496, 2022.
PubMed
10) Hause A M, Baggs J, Marquez P, et al : Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022. MMWR Morb Mortal Wkly Rep 71 : 347-351, 2022.
PubMed
11) Keshavarz P, Yazdanpanah F, Rafiee F, et al : Lymphadenopathy Following COVID-19 Vaccination : Imaging Findings Review. Acad Radiol 28 : 1058-1071, 2021.
PubMed
12) Block J P, Boehmer T K, Forrest C B, et al : Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination-PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep 71 : 517-523, 2022.
PubMed
13) Munro A P S, Janani L, Cornelius V, et al : Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST) : a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398 : 2258-2276, 2021.
 
14) Teijaro J, R Farber D L : COVID-19 vaccines : modes of immune activation and future challenges. Nat Rev Immunol 21 : 195-197, 2021.
PubMed
15) Turner J S, O'Halloran J A, Kalaidina E, et al : SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596 : 109-113, 2021.
PubMed
16) Kazama I, Maruyama Y.Murata Y : Suppressive effects of nonsteroidal anti-inflammatory drugs diclofenac sodium, salicylate and indomethacin on delayed rectifier K+-channel currents in murine thymocytes. Immunopharmacol Immunotoxicol 34 : 874-878, 2012.
PubMed
17) 風間逸郎, 佐藤憲治, 吉川陽大, 齊藤泰功, 三上千佳子, 和田尚, 阿部成雄 : 新型コロナウイルス陽性者における第6波と第7波での症状の比較. 看護技術 68 (13) : 67-72, 2022.
 
18) Kreier F : Long-COVID symptoms less likely in vaccinated people, Israeli data say. Nature, 2022. doi : 10.1038/d41586-022-00177-5
 
19) Kazama I : Stabilizing mast cells by commonly used drugs : a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther 14 : 259-261, 2020.
PubMed
20) Wong R S Y : COVID-19 vaccines and herd immunity : Perspectives, challenges and prospects, Malays J Pathol 43 : 203-217, 2021.
PubMed
21) Kazama I : Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis. Clin Mol Allergy 19 : 25, 2021.
 

【Diagnosis】

P.1520 掲載の参考文献
1) 三宅侃, 倉智博久, 森重健一郎, 他 : 卵胞刺激ホルモン (FSH). 日本臨床 53 : 285-287, 1995.
Medical*Online
2) 仲野良介 : ゴナドトロピン (FSH, LH). 臨床検査 38 : 85-87, 1994.
 
3) 井村裕夫 (編) : 内分泌・代謝病学, 第3版. pp.99-112, pp.336-351, pp.352-368, 医学書院, 東京.
 
4) Kern G : 婦人科学. pp.4-7, 文光堂, 東京, 1981.
 
5) La Marca A, F J Broekmans, A Volpe, et al : Anti-Mullerian hormone (AMH) : what do we still need to know? Hum Reprod 24 : 2264-2275, 2009.
 
6) Eilertsen TB, Vanky E, Carlsen SM : Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome : can morphologic description be replaced? Hum Reprod 27 : 2494-2502, 2012.
PubMed
7) 岩佐武, 松崎利也, 田中尚子, 他 : ARCHITECTアナライザーi2000(R) を用いた血中LH, FSHおよびPRL の全自動測定システムの臨床的検討. 産婦人科治療 87 : 243-251, 2003.
Medical*Online
8) Takahashi K, Ozaki T, Okada M, et al : Increased prevalence of luteinizing hormoneβ-subunit variant in patients with premature ovaian failure. Fertili Steril 71 : 96-101, 1999.
 
9) Takahashi K, Ozaki T, Kanesaki H, et al : Successful Pregnancy in a Woman with ovarian Failure Associated with Mutation in theβ-Subunit of Luteinizing Hormone. Horm Res 55 : 258-263, 2001.
 
10) Budi Wiweko, Mila Maidarti, M. Dwi Priangga, et al : Anti-mullerian hormone as ad diagnostic and prognostic tool for PCOS patiens. J Assist Reprod Genet 31 : 1311-1316, 2014.
 
11) Bungum L, Jacobsson AK, Rosen F, et al : Circadian variation in concentration of anti-Mullerian hormone in regularly menstruating females : relation to age, gonadotrophin and sex steroid levels. Human Reprod 26 : 678-684, 2011.
PubMed

書評

最近チェックした商品履歴

Loading...